rupatadine Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Rupatadine is a second generation antihistamine and platelet-activating factor antagonist used to treat allergies. It was discovered and developed by Uriach and is marketed as Rupafin and under several other trade names.   Wikipedia

Chemistry

  • SMILES: Cc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc5cccnc35)CC2)c1
  • InChIKey: WUZYKBABMWJHDL-UHFFFAOYSA-N
  • Mol. Mass: 415.97
  • ALogP: 5.63
  • ChEMBL Molecule:
    rupatadine  
More Chemistry

Pharmacology

Alternative names

8-chloro-6,11-dihydro-11-(1-((5-methyl-3-pyridinyl)methyl)-4-piperidinylidene)-5h-benzo(5,6)cyclohepta(1,2-b)pyridine | alergoliber | pafinur | rinialer | rupafin | rupatadine | rupax | ur 12592 | ur-12592

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (1)


 

Rhinitis

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Arthritis, Rheumatoid (Phase 3)

Chronic Urticaria (Phase 3)

Healthy Volunteers (Phase 4)

Hypersensitivity (Phase 4)

Hypersensitivity, Immediate ()

Mastocytosis (Phase 2/Phase 3)

Rhinitis, Allergic (Phase 4)

Urticaria (Phase 3)

Volunteers (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue